Aryl Nitrile Modulators Targeting CXCR3 Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and immunoregulatory disorders, such as asthma, psoriasis, inflammatory bowel disease, and autoimmune pathologies like rheumatoid arthritis and multiple sclerosis, lack effective modulators for the CXCR3 chemokine receptor, which plays a crucial role in T-cell trafficking and inflammation.
Innovation Solution
Development of novel aryl nitrile modulators that specifically target the CXCR3 receptor, including compounds with specific structural formulas (e.g., IV, V, VII, VIII) that can be used in pharmaceutical compositions to treat these disorders by modulating CXCR3 function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and immunoregulatory disorders are used, then existing therapeutic options are available, but effective modulators for the CXCR3 chemokine receptor are lacking
Solution Approach 1:
The patent segments the broad category of inflammatory disorder treatments into specific receptor-targeted therapies. By developing compounds that specifically modulate the CXCR3 receptor, the invention divides the general therapeutic approach into a targeted mechanism, providing reliable and effective treatment for conditions mediated by this receptor while maintaining adaptability across multiple disease states.
Solution Approach 2:
The invention changes the therapeutic parameter from general anti-inflammatory agents to specific CXCR3 receptor modulators. This parameter change enables both reliable therapeutic effectiveness and adaptability, as the compounds can be applied to treat multiple inflammatory and immunoregulatory disorders through a unified mechanism of action at the CXCR3 receptor level.
2Reliability
If novel aryl nitrile modulators targeting CXCR3 are developed, then effective treatment for inflammatory disorders is achieved, but the structural complexity of the compounds increases
Solution Approach 1:
The patent extracts the essential pharmacophoric elements required for CXCR3 receptor modulation and incorporates them into the aryl nitrile core structure. By identifying and isolating the critical structural features (such as the aryl nitrile group and specific substituent patterns), the invention achieves therapeutic effectiveness while maintaining a manageable structural framework that can be systematically optimized.
Solution Approach 2:
The compounds represent composite molecular structures combining an aryl nitrile core with various substituent groups (such as heterocyclic rings, alkyl chains, and functional groups). This composite approach allows the molecule to achieve the necessary complexity for specific receptor binding while organizing the structural elements in a systematic way that facilitates drug development and optimization.
3Measurement precision
If specific structural formulas (IV, V, VII, VIII) are used to target CXCR3, then selective receptor modulation is achieved, but the difficulty of synthesis and manufacturing increases
Solution Approach 1:
The patent employs preliminary action by designing synthetic routes that establish the core aryl nitrile structure and key substituent positions early in the synthesis process. By pre-forming the essential structural framework and incorporating protecting group strategies, the invention achieves high receptor binding specificity while reducing the overall complexity of the synthetic sequence and improving manufacturability.
Solution Approach 2:
The invention uses intermediary compounds and building blocks that facilitate the assembly of the final high-specificity molecules. By developing modular synthetic approaches with well-defined intermediates, the patent enables the production of compounds with precise receptor binding characteristics while simplifying the manufacturing process through standardized intermediate preparation and assembly steps.
Data Source
AI summary
Compounds, (I) compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides aryl nitrile compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, type I diabetes, asthma, psoriasis and inflammatory bowel disease. All definitions are as given in claim 1.